Pharmacokinetics of mercaptopurine

Area of Science:

• Pharmacology
• Toxicology
• Biomedical Engineering

Background:

• Mercaptopurine is a crucial chemotherapeutic agent.
• Understanding its distribution is vital for optimizing treatment and minimizing toxicity.
• Limited data exists on mercaptopurine's precise tissue distribution patterns.

Purpose of the Study:

• To investigate the anatomical distribution of mercaptopurine in rat tissues.
• To develop and validate physiologically based pharmacokinetic (PBPK) models for mercaptopurine.
• To predict human plasma levels of mercaptopurine using validated models.

Main Methods:

• Administered mercaptopurine intravenously to rats at 2.5 and 25 mg/kg.
• Analyzed plasma and tissue samples using radioisotopic dilution and spectrofluorometric techniques.
• Developed PBPK models to simulate mercaptopurine concentrations in various organs and tissues.

Main Results:

• Determined significant tissue-plasma concentration ratios: liver (approx. 4.0), kidney (approx. 2.4), spleen (approx. 1.7), muscle (approx. 1.4), gut lumen (approx. 3), and bone marrow (approx. 0.35).
• PBPK models demonstrated good agreement between predicted and experimental plasma and tissue mercaptopurine concentrations.
• Predicted human plasma levels showed reasonable concordance with existing clinical data.

Conclusions:

• Mercaptopurine exhibits variable distribution across different rat tissues.
• Validated PBPK models provide a reliable tool for simulating mercaptopurine pharmacokinetics.
• The models show potential for predicting human mercaptopurine exposure and informing clinical applications.